Invitrocue (ASX:IVQ) has screened the first commercial Onco-PDO customer in Singapore for the indication of colorectal cancer.
The company’s Onco-PDO test provides an overview of how a patient’s cancer cells respond to different chemotherapies, ranking these therapeutics based on their effectiveness in delivering a positive response.
Importantly, this approach allows oncologists to develop better informed and more personalised treatment strategies for patients.
Positive response from oncologists
Screening the PDO models for the first paying customer signals the initial commercial applications of Invitrocue’s technology and approach in the Asia Pacific region.
Invitrocue chief executive Dr Steven Fang said: “We are incredibly excited to have screened our first patient in Singapore against the OncoPDO drug sensitivity test, and are encouraged by the response and interest so far from both local and international oncologists in using this technology with their patients to better inform their decision-making process when dealing with a variety of cancer types.”
More patients identified to use the test
Invitrocue has identified key medical channel partners for Singapore and will also be receiving patients from Hong Kong who are looking to utilise the Onco-PDO platform.
All clinical work to offer Onco-PDO services is being carried out at the joint laboratory established last year between the Genome Institute of Singapore (GIS) and Invitrocue.
The laboratory is located at A*STAR, the Singapore government’s Agency for Science, Technology and Research.